Pharmaceutical Executive Daily: Eli Lilly Enters $1 Billion Research Collaboration with Seamless Therapeutics
Jan 28, 06:35 PM
Share
Subscribe
In today’s Pharmaceutical Executive Daily, Insilico Medicine and Qilu Pharmaceuticals launch a $120 million collaboration to advance AI-driven cardiometabolic therapies, Eli Lilly enters a billion-dollar research partnership targeting hearing loss, and industry leaders examine what it takes to bring breakthrough rare disease products to patients.